Merus MRUS 深 滬
已收盤 10-24 16:00:00 美东时间
94.88
+0.460
+0.49%
華盛通- 最 高95.06
- 今 開94.48
- 成交量 250.71万股
- 最 低 94.40
- 昨 收 94.42
- 總市值 70.66亿
- 52周最高 95.06
- 市盈率 靜 --
- 換手率 3.37%
- 52周最低 33.19
- 委 比 44.17%
- 總股本 7447.67万
- 歷史最高 95.06
- 量 比 1.10
- 振 幅 0.70%
- 歷史最低 7.255
- 每 手 1
- 風險率 14.85%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Merus Announces Interim Clinical Data From Ongoing Phase 2 Trial Of Bispecific Antibody Petosemtamab In Metastatic Colorectal Cancer In Combination With FOLFOX/FOLFIRI
– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed)– 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct.
10-24 22:04
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
Merus N.V. announced interim results from a phase 2 trial of petosemtamab in metastatic colorectal cancer (mCRC). In 1L left-sided mCRC, 100% response rate was observed (n=8). In 2L mCRC, a 62% response rate was noted (n=13). Petosemtamab showed promising efficacy and a consistent safety profile across treatment lines, with no new safety signals identified. These findings highlight its potential as a transformative treatment for mCRC patients.
10-24 14:00
Why Is Genmab Stock Trading Lower On Monday?
Genmab reported a 50% response rate and durable results for Rina-S in advanced endometrial cancer, with manageable side effects and no major toxicities.
10-20 23:57
Merus Reveals Petosemtamab In Metastatic Colorectal Cancer Abstract Selected For Plenary Session Oral Presentation At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics, Being Held In Boston, Massachusetts On October 22-26, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific
10-14 00:04
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Merus N.V. announced the acceptance of two abstracts on petosemtamab, a bispecific antibody targeting EGFR and LGR5, for presentation at the AACR-NCI-EORTC conference in Boston. Initial interim data from a phase 2 trial evaluating petosemtamab in metastatic colorectal cancer will be presented in a plenary session on October 24, 10:00-11:40 a.m. ET. The same data will also be available in a poster session on October 24, 12:30-4:00 p.m. ET. Additio...
10-13 16:00
贝达药业:贝达已获得Merus公司独家授权许可MCLA-129项目在中国的开发和...
有投资者在深交所互动平台向贝达药业提问："请问董秘，今日公司合作伙伴Merus NV宣布，Genmab A/S以每股97美元现金要约收购其全部股份。这对公司正在...
10-09 17:29
【国盛医药】周专题&周观点：十一期间医药都有哪些大事？【总第416期】
（来源：国医盛视） 一、医药核心观点 9.29-10.7 回顾与周专题： 十一期间（9.29-10.7）港股申万医药指数上涨8.33%...
10-08 18:54
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
Leerink Partners Downgrades Merus to Market Perform, Raises Price Target to $97
Leerink Partners analyst Andrew Berens downgrades Merus (NASDAQ:MRUS) from Outperform to Market Perform and raises the price target from $95 to $97.
10-06 19:26
Mercury Systems and Nightwing Collaborate to Enhance Cybersecurity for Aerospace and Defense Systems
Mercury Systems and Nightwing have partnered to enhance Mercury’s hardware cyber resiliency using Nightwing’s technology. The collaboration provides pre-integrated cybersecurity solutions for government customers, reducing total cost of ownership and strengthening mission-critical systems against evolving cyber threats. This partnership combines Mercury’s trusted hardware with Nightwing’s advanced cyber resilience expertise to deliver more secure...
10-06 11:00
